Exclusive Physician Survey Results on GLP-1 Receptor Agonists: The Hype Is Real
Three-quarters of primary care survey respondents prescribe GLP-1 RAs for weight loss and half get questions daily about the drugs. See all the results.
Have you prescribed GLP-1 RAs to treat obesity in your practice?
How often do your patients inquire about GLP-1 RAs for weight loss?
Do the patients who inquire about GLP-1 RAs meet the criteria for overweight/obesity indicated in labeling of the medications?
Do you feel patients have realistic expectations of the weight loss outcomes associated with use of GLP-1 RAs?
Are you concerned about your patients attempting to procure GLP-1 RAs from online sources without your knowledge?
How do you typically integrate GLP-1 RAs into your treatment plans for management of obesity?
How often, in your experience, do your patients prescribed GLP-1 RAs experience significant adverse effects?
How effective do you find GLP-1RAs in achieving weight loss goals for your patients?
Do you consider GLP-1 RAs to be cost-effective for weight loss?
Do your patients frequently face insurance coverage challenges when obtaining GLP-1 RAs?
Do you anticipate the use of GLP-1RAs for weight loss increasing in the future?
The most pressing unanswered questions about the use of GLP-1 RAs for weight loss:
How to make the treatment more affordable for patients
We need a greater understanding of any long-term health consequences/side effects/complications
Availability of the drugs through proper channels
GLP-1 RA survey respondents' specialty areas broke down as:
Family Practice: 46%
Internal Medicine: 34%
Other: 20%
Half of family practice and internal medicine specialists field patient questions on a daily basis about glucagon-like peptide 1 receptor agonists (GLP-1RAs) for weight loss while more than one-third are queried weekly, according to results from an early October survey by primary care partner websites Patient Care and Medical Economics.
The survey also revealed concern among frontline health care professionals about the popularity and shortages of the antiobesity medications, reflected by responses from more than three-quarters that they worry their patients will seek out GLP-1 RAs from online sources without consulting them first.
Click through the rest of the findings on what primary care clinicians think about this class of drugs, how they select patients for GLP-1RA therapy, and what they feel are the most important unanswered questions about the "miracle" drugs.
